BWI: Sun Pharma to License Key Escitalopram Patent Applications to Lundbeck

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Friday, July 10, 2009 07:15 PM IST (01:45 PM GMT)
Editors: General: Consumer interest, Law & justice; Business: Business services, Healthcare, biotechnology & pharmaceutical; Healthcare
--------------------------------------------------
Sun Pharma to License Key Escitalopram Patent Applications to Lundbeck
To Receive Upfront Payment and Royalties

Mumbai, Maharashtra, India, Friday, July 10, 2009 -- (Business Wire India) -- Sun Pharmaceutical Industries Ltd. ("Sun Pharma", collectively with its 100% subsidiary) announced that along with Caraco Pharmaceutical Laboratories, Ltd ("Caraco"), it had entered into agreements with Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., and H. Lundbeck A/S (collectively, "Forest") to settle the legal proceedings related to Lexapro® (escitalopram oxalate) tablets.

Among other things, with respect to Sun Pharma and Caraco, the agreement contains the following provisions:

1. Sun Pharma will license to Lundbeck on a worldwide basis certain patent applications related to the synthesis of escitalopram and citalopram in exchange for an upfront payment and, if the technology is used, royalties on sales.

2. Forest will provide licenses to Caraco for any patents related to Lexapro® and with respect to the marketing of Caraco's generic version of the product as of the date that any third party generic that has received final approval from the FDA enters the market other than an authorized generic or the first filer with Hatch-Waxman related exclusivity.

3. Caraco will take over the commercialization and sale of several products from Forest's Inwood business. Caraco will pay Forest an undisclosed advance against royalties and royalties on net sales of these products.

4. Forest will reimburse Caraco for a portion of their costs related to this litigation.

These agreements will be subject to review by the U.S. Federal Trade Commission.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.


CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Extn: 605, +91 (22) 66455605, +91 9867010529, uday.baldota@sunpharma.com
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Extn: 606, +91 (22) 66455606, +91 9821923797, mira.desai@sunpharma.com

KEYWORDS
CONSUMER, LAW, BUSINESS SERVICES, HEALTHCARE, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com